Error message

User warning: The following module is missing from the file system: admin_menu. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1138 of /mnt/stor8-wc1-dfw1/408138/

Cannabis Stocks News

5/21 8:00am

Amfil Technologies Inc. Reports $2,445,949 In Fiscal Q3 2018 Revenue, Up 35% Year Over Year

mfil Technologies Inc. (OTC Pink: MFE) is pleased to report a 35% increase in year over year Fiscal Q3 Revenue at $2,445,949, up from $1,809,064 for Q3 2017, with gross profits up from $827,874 to $1,450,649. Comparative year over year growth for the quarter saw a 35% increase despite Q3 being the company’s historically slowest quarter. The January to March quarter is not usually a large quarter for distribution which is a large part of the company’s overall revenue stream and is also affected by returns on holiday items, redemption of gift cards, and the industry-wide attendance dips during the post-holiday season, all which effects the bottom line.
5/21 8:00am
CIIX, Inc. Announces That Its Subsidiary, Inc. Has Expanded Its Sales Force in an Effort to Grow the Division's Revenues Domestically

EW YORK , May 21, 2018 /PRewswire/ --, Inc. (OTCQB: CIIX) ("CIIX" or the "Company"), the premier financial information website for Chinese-speaking investors, ...
5/21 7:15am

Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space

ajor equities: AbbVie Inc. (NYSE: ABBV), Bristol-yers Squibb Co. (NYSE: BY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
5/21 12:55am

$Amfe DD

Distribution, Distributor, Investments, Investors, Management, Organic
MFE - Institutional Investors, Organic MJ, Revenues Surging mfil Technologies has recently seen two institutional investors take a position, Oxbow dvisors and Summit Global Investments. The two funds have over $1 Billion at their disposal. MFE is set to uplist in the coming weeks. ssets Under Management (UM) Oxbow dvisors: $1.483 Billion Summit Global Investments: $$720 Million Combined Total UM: $2.203B Managed Securities (s of Q1 2018) Oxbow dvisors: $490.5M Summit Global Investments: $628.5M Combined Managed Securities: $1.119B Oxbow dvisors Summary: Summit Global Investments Summary: Recent MFE Highlights: $11,653,872 in revenues through 3 quarters in fiscal 2018. Entire fiscal 2017 was $6,630,973. Gro3 subsidiary is currently outfitting a Canadian MJ Cultivator with the Gro3 Organic RotoGro Systems. The cultivator is in stage 6 of 7 for licensing from Health Canada. Here is the blueprint for the facility: Working on penetrating Columbia on a JV initiative involving local government. 4th corporate Snakes & Lattes Board Game Cafe location in Tempe, Z set to open late summer. private investor has agreed to fully fund seven Snakes & Lattes locations in the United States Southwest. MFE set to acquire Morning, a board game publisher and distributor located in France. cquisition expected to close by end of May, and is being negotiated as a cash deal. MFE holds distribution rights to many popular games such as Cards gainst Humanity and Exploding Kittens. submitted by /u/Fiddli [link] [comments]
5/20 9:41pm

MGC Pharmaceuticals on high as Malta legalises medical cannabis

Cannabis, Pharmaceuticals
pecialist pot-stock, MGC Pharmaceuticals (AX:MXC), this morning revealed that the Maltese parliament has passed final legislation for the approval ...
5/20 5:10pm

Sweet Diagram of the Endocannabidnoid System (credit Mark Rau)

5/20 9:43am

The Maricann Greenhouse: (same designer for TWEED, THCX, BE) -

5/20 6:30am
APH.V, ASX:CMY Acquisitions

Better Marijuana Stock: Aphria vs. Organigram Holdings

Acquisitions, Cannabis
he company's acquisitions of Nuuvera and Broken Coast Cannabis earlier this year position Aphria as a major player in two key growth markets.
5/20 1:49am

TWMJF (WEED) breakdown, 5/19/18

Investors, Management, News
here is no question, WEED is in an uptrend. Day traders know that WEED cannot short Monday. Monday is a day of OC trading that for the most part, does not allow shorts. Monday will be a HUGE day for WMJF, up nearly 15%. Smart OC traders will ride the day up, and sell and the end of the day because the shorts come back on uesday to hit the over-bought conditions. Be smart traders. Buy WMJF at early AM, ride the green all day. ake profits at the end of the day. his is what will happen. Look at WEED's (WMJF's) history. Huge green days on Canada closed days, then pullbacks on the day after. as the shorts hit. WMJF will have one of it's biggest days on record Monday. Even higher if NYSE hits as CGC. his stock has nowhere to go up, and anyone who tells you otherwise is shorting and trying to cover. his is as BULL as a market gets. Watch 10-20% gains Monday on WMJF with low-volume, as shorts take a day off and WEED will not be trading. Want to make a quick 15% on your money? Buy WMJF first thing Monday, before it runs. Sell an hour before market close. I'm not on here to pump any stock. It's downright obvious what will happen to WMJF on Monday, and there is a lot of money to be made. I made millions. I'm on here now to help other people improve their lives. I'm now retired comfortably and feel the need to help other people. While I still have millions to be made, WMJF WILL RUN HEAVY GREEN MONDAY. No doubt in my mind. Don't listen to people on here that say otherwise. If you want to make some serious money on Monday, buy WMJF early AM and sell about 3pm. Don't wait until 3:30pm, because profit taking will already be under way. Maybe even 2:30 if charts are showing that. I want you all to make money, and I'm trying to help. his is not a pump by any means. I will be buying about 300,000 shares of WMJF first thing on dip Monday morning, and unloading about half of that at 2:30pm. he other half is being held long anticipating NYSE listing and institutional investors. hese people saying AH is coming... lol. AH is only 18% away. AH was based off speculation. New AH is astronomical compared to chart analysis. Charts are supposed to tell the future from the past. However, in a market like this... full-scale legalization has never happened. here is no credible past with which to compare. his is a budding industry with credible financials. Watch CGC to $60 USD by August 1st. Small dip in August, followed by another crazy bull run September thru December. Don't believe me? Look what these stocks have done for the last 5 years in late-summer through January. Nothing but bull. Given legalization (92% chance), this market is in it's baby stages. People who keep pointing out market cap are so mistaken. Canopy Growth Corp. has operations in about 10 world-wide countries, approximately 30B worth of market cap. Canada (as Bruce has stated) offers them about 40% market cap of the recreational Canadian market. By estimations, this adds about 6-10B of market cap. his company is undervalued by almost 4x, even with current valuations priced-in. here is a reason WEED is outperforming other stocks on a consistent basis. hey are the market king, with the smartest management team. hey understand shareholders and their value and importance, and place the interest of shareholders first. his can be demonstrated by Bruce unleashing acquisition news at the same time as NYSE news, basically cancelling the negative affect of a very small share dilution. Expect to see about $100/share by year's end. I'm a private investor that does my heavy DD. his stock is INSANELY cheap right now. I've been loading long term, and taking advantage of short term NR's. Averaging down is past news. I'm accumulating as much as possible right now. We will never see these stock prices again. Agree with me or not, I'm trying to help hundreds/thousands of you with making a pretty penny on Monday. However, we will see a small 2% dip about 15 mins after open. After that, it's off to the races. Expect some SERIOUS profit taking at the end of the day, placing us almost down to opening price. Haters can argue. However, this is just about fact. Make money, that's what this sub is all about, right? EDI: grammar submitted by /u/Jefferzon420 [link] [comments]
5/19 7:15am

Better Marijuana Stock: Insys Pharmaceuticals vs. Cara Therapeutics

Growers, Pharmaceuticals
here are several kinds of marijuana stocks. Some are about as pure-play as you can get, like stocks of marijuana growers. Others make a significant ...
5/18 8:03pm

Aphria Has 115% Upside, Says PI Financial

5/18 7:48pm

Finally Options on TWMJF (WEED)

hat do you guys think about leveraging some options on CGC after the NYSE listing. I've been very jealous of my Canadian counter parts who have been able to do so much more than buy shares on the OTC. I read somewhere in these forums awhile back (about CRON) that Robinhood has a day or two delay to access a new listing in the NYSE or NASDAQ. hat do you guys think about buying some options immediately post-NYSE uplisting and the (fingers crossed) mad US millennial money pouring in? I can't imagine how out of whack some of the valuations may get. No one knows what may happen, but this shit could go crazy. submitted by /u/Meadhead81 [link] [comments]
5/18 7:48pm

Finally Options on TWMJF (WEED) - CGC

hat do you guys think about leveraging some options on CGC after the NYSE listing. I've been very jealous of my Canadian counter parts who have been able to do so much more than buy shares on the OTC. I read somewhere in these forums awhile back (about CRON) that Robinhood has a day or two delay to access a new listing in the NYSE or NASDAQ. hat do you guys think about buying some options immediately post-NYSE uplisting and the (fingers crossed) mad US millennial money pouring in? I can't imagine how out of whack some of the valuations may get. No one knows what may happen, but this shit could go crazy. submitted by /u/Meadhead81 [link] [comments]
5/18 4:30pm

Fission Announces Changes to the Board of Directors

ISSION URANIUM CORP. ("ission" or the “Corporation") (CU.TO) (CUU) (2U.) today announced that Jianhua Xing has resigned as a member of the board of directors of the Corporation (the “Board”), effective immediately. The Corporation also announced today that Deshao Chen has been appointed to the Board, effective immediately. CGN Mining Company Limited (“CGN Mining”) is entitled, pursuant to a subscription agreement with the Corporation dated January 11, 2016, to nominate up to two directors to the Board in accordance with the terms of the subscription agreement.
5/18 2:59pm

Surna Reports Q1 2018 Results

5/18 1:03pm

Newbie here. What are your recommendations?

ould you buy a certain stock or an index fund of weed stocks? ould you play it safe and divide your money into multiple companies? So far my top picks are, after research: Canopy Aphria Aurora submitted by /u/valarmorgulis528 [link] [comments]
5/18 12:53pm

New to weed. Is $WEED any different than $TWMJF?

f 'm buying on TD Ameritrade, for instance, would i just be buying TWMJF instead of WEED? Thanks! submitted by /u/valarmorgulis528 [link] [comments]
5/18 10:30am

How Do Analysts Rate Canaccord Genuity?

Cannabis, News
n May 16, CannTrust (CNTTF) dropped almost 8.3% on news of further dilution of the stock. The company announced an upsizing of its previously announced offering in which the company will grant its underwriters, Canaccord Genuity and GMP Securities, the option to purchase an additional 1.5 million shares at a price of 9 Canadian dollars. The stock has delivered a loss of 3.2% YTD (year-to-date) but has performed better than industry stocks (MJ) like Aphria (APHQF) and Aurora Cannabis (ACB) (ACBFF).
5/18 9:20am

Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?

bbott (BT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5/18 8:15am

5 Things AbbVie Investors Need to Know

Investors, Products
bbVie's top executives answer tough questions about the company's products and pipeline.
5/18 8:01am

See what the IHS Markit Score report has to say about Abbott Laboratories.

bbott Laboratories NYSE:BT
5/18 5:01am

Marapharm Ventures Inc. Announces Non-Brokered Private Placement Unit Offering

5/17 7:03pm

Legal weed could mean fewer opioid prescriptions: Cannabis CEO

im Cramer sits down with Canopy Growth CEO Bruce Linton after his company applied to list its shares on the New York Stock Exchange.
5/17 4:48pm

DigiPath $DIGP Update on California Testing Lab!

5/17 12:55pm

Forget Cara Therapeutics' Earnings -- Here's the Real News

his little biotech could win by playing small ball.
5/17 12:42pm

Medifirst Solutions Launches Specialty Prescription Billing and Pharmacy Solutions Division

s recently announced, Concierge Concepts Rx (CCRx), a new division of Medifirst Solutions, will provide a unique niche billing service to independent pharmacies who are struggling to maintain profitability. Medifirst is pleased to announce that Walter Molokie, RPh has joined the company as CEO of CCRx.
5/17 10:49am


’m considering selling these two but would like to know if anyone on here thinks should hold, and if so, why? submitted by /u/B4bradley [link] [comments]
5/17 9:36am

Abattis Signs Agreement with Cannamedix to Support the Development and Commercialization of CBD-infused Natural Health Products

CBD, Development, Products
5/17 9:03am
APH.V Enters

Major U.S. Alcohol Distributor Enters Canadian Cannabis Market with Aphria Deal – New Cannabis Ventures

Alcohol, Cannabis, Distributor
5/17 9:00am

Digipath Makes Progress with its Cannabis Testing Lab Joint Venture in Humboldt County, CA

Cannabis, Growers, Media, Testing, Cultivation
AS VEGAS, May 17, 2018 /PRNewswire/ -- Digipath, Inc. (DIGP), a service-oriented independent testing laboratory and media firm focused on the developing cannabis market, is pleased to provide this update on its previously announced joint venture to operate a cannabis testing laboratory in Humboldt County, CA. The cannabis lab will be well positioned to service all Humboldt County growers as well as growers located in neighboring Mendocino County. This is significant, as Santa Barbara, Mendocino, Monterey, and Calaveras Counties account for 74% of the 1,256 cultivation licenses issued so far in California, with Humboldt County alone representing 20% of this total.
5/17 8:30am

Namaste Announces Medical Cannabis Supply Agreement with Tetra Natural Health, to Sell RX Princeps Through Cannmart

Cannabis, Distribution
ANCOUER , May 17, 2018 /CNW/ - Namaste Technologies Inc. ("Namaste" or the "Company") (TSX:N.)(M5BQ.F)(NXTTF) is pleased to announce that the Company has signed a Supply Agreement (the "Supply Agreement") for the sale and distribution of RX Princeps the medicinal marijuana brand of Tetra Natural Health, a division of Tetra Bio-Pharma ("Tetra Bio-Pharma")(TBP.)(TBPMF), whereby Namaste will purchase RX Princeps from Tetra Natural Health which will be sold through Namaste's wholly owned subsidiary and Access to Cannabis for Medical Purposes ("ACMPR") medical cannabis "sales-only" facility, Cannmart Inc. ("Cannmart").
5/17 8:30am
ETST Fully Reporting

Earth Science Tech, Inc.’s (ETST) Advancement to Fully Reporting Status Covered by NetworkNewsAudio

News, Science
EW YORK, May 17, 2018-- via etworkWire– etworkewsWire, a multifaceted financial news and publishing company for business, today announces the audio version of the press release titled“ Earth Science ...
5/17 8:00am

Tetra Natural Health Signs a Supply Agreement with Namaste Technologies for the Marketing and Distribution of Rx Princeps™, its Premium Medicinal Cannabis Product

Cannabis, Distribution, Marketing
etra Natural Health a division of etra Bio-Pharma Inc. (“etra” or the “Company”) (BP.V) (BPMF) and - Namaste echnologies Inc. (“Namaste” or the “Company”) (SX-V:N) (M5BQ.F) (NXF) is pleased to announce that the Company has signed a Supply Agreement ( the “Supply Agreement”) for the sale and distribution of Rx Princeps™ the medicinal cannabis brand of etra Natural Health, a division of etra Bio-Pharma (“etra Bio-Pharma”)(BP.V) (BPMF), whereby Namaste will purchase Rx Princeps™ from etra Natural Health which will be sold through Namaste’s wholly owned subsidiary Access to Cannabis for Medical Purposes (“ACMPR”) medical cannabis “sales-only” facility, Cannmart Inc. (“Cannmart”). he agreement also includes the sales of etra Natural Health’s specially designed inhalation device, air filters and its Munchies B Gone gum.
5/17 8:00am

Spearmint Looking to Start Operations on Gold Prospects in British Columbia

ancouver, British Columbia--(Newsfile Corp. - May 17, 2018) - Spearmint Resources Inc. (TSX: SRJ) (OTC Pink: SPMTF) (FSE: A2AHL5) ("SRJ" or the "Company") wishes to announce that the company is planning to commence operations shortly on its numerous gold properties in British Columbia. James Nelson, President of Spearmint states, "We look forward to starting up operations on our properties located within the Golden Triangle of British Columbia. We anticipate a lot of work ...
5/17 7:47am
APH.V Clinical Trials

Cannabis is Fueling the Next Era of Medical Revolution

Cannabis, CBD, Development, Distribution, Events, Food, Growing, Investment, Investments, Investors, Marketing, Media, Medical Marijuana, News, Pharmaceutical Grade, Production, Products, Research, Synthetic, Vaporizers, Vaporizers, Pharmaceuticals, Intellectual Property, Security
alk of legalizing marijuana throughout North America has been growing like a weed. Up to 88% of Americans favor its medicinal use, thanks to a growing body of research supporting marijuana's use for medical purposes. Some studies even suggest it can be used for a variety of medical issues including pain, nausea, loss of appetite, Parkinson's disease, inflammatory bowel disease, post-traumatic stress disorder, epilepsy, and multiple sclerosis and even traumatic brain injuries - the list goes on. Several legitimate players in the medical marijuana sector include Scythian Biosciences Corporation (SX-V: SCYB) (OC: SCCYF), GW Pharmaceuticals (NASDAQ: GWPH), OrganiGram Holdings Inc. (SX-V: OGI) (OC: OGRMF), Corbus Pharmaceuticals (NASDAQ: CRBP) and Aphria Inc. (OC: APHQF) (SX: APH). As more than 29 U.S. states plus Washington, D.C. have approved its medicinal use, and as eight states have approved its recreational use, it's clear that legal marijuana stocks are here to stay. On top of that, 61% of Americans now believe marijuana use should be legal. Whether it be Scythian Biosciences Corporation's cannabis-based treatment for traumatic brain injury or GW Pharmaceuticals' Epidolex drug currently under review for childhood epilepsy, investors are seeing promising steps forward for the medical marijuana industry. Medical Marijuana Sweeping the Continent wenty years after California legalized medical marijuana, it's become a multi-billion dollar business, says USA oday. "Millions of Americans believe that marijuana helps them. hey say it relieves pain, improves their appetite and eases the side effects of chemotherapy. Others swear by it for helping with PSD or anxiety or seizures. Millions use it just to sleep better." Aside from PSD and anxiety, GW Pharmaceuticals has been picking up momentum on indications the U.S. Food and Drug Administration may approve its cannabis-derived drug Epidolex for treatment of seizure symptoms of Lennon-Gastaut syndrome (LGS) and Dravnet syndrome. Peak sales are estimated to be $500 million if approved. Zynerba Pharmaceuticals is working on treatments for Fragile X Syndrome (a genetic condition that causes developmental issues), developmental and epileptic encephalopathies, adult refractory seizures, and ourette syndrome. Corbus Pharmaceuticals is working on Lenabasum (formerly known as anabasum), a synthetic, oral, small-molecule, selective cannabinoid receptor type 2 (CB2) agonist that preferentially binds to CB2 expressed on activated immune cells and fibroblasts for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus. Scythian Biosciences Corporation (SX.V: SCYB) (OC: SCCYF) also is just beginning to gain momentum, advancing its treatment efforts for concussions and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy. he Cannabis Commitment to Brain rauma Remedies Scythian Biosciences is committed to advancing prevention and treatment efforts for concussion and traumatic brain injury with its proprietary cannabinoid-based combination drug therapy. Recently, the company teamed up with Isodiol International Inc., an industry leader in pharmaceutical grade phytochemical compounds production, as well as CBD consumer products development. his partnership will allow Scythian to tap into Isodiol's experienced, top tier team of chemists, technicians, and professors that yield the purest government-approved CBD available. Particularly, the way Scythian accomplishes its top-tier brain-trauma medication is through a combination of drug molecules called CB2 receptor agonists and NMDA receptor antagonists. CB2 receptor agonists, principally a compound known as cannabidiol (CBD), is a non-psychoactive cannabinoid compound naturally found in the marijuana plant that is known to resolve inflammation without the associated high, quickly, effectively, and systemically shutting the inflammatory response down. NMDA antagonists inhibit white blood cell activity within injured brain tissue, stopping cytokine release and further brain damage. CB2 agonists modulate the inflammatory response itself, easing the initial swelling and the resulting pressure of injured brain tissue against the skull. Scythian's ambitions doesn't stop there. he company has recently announced its letter of intent to acquire MMJ International Investments Inc., sole holder of an Argentina-based pharmaceutical import and distribution company. his move, along with Isodol's ability to export the pure, natural CBD anywhere in the world, including Argentina, Colombia, and Jamaica, could exponentially expedite Scythian's international footprint and industry advancements. he Need for Medical Marijuana he medical community believes they've found an alternative treatment to help patients - medical marijuana. Medical researchers have already found that it can slow the progress of protein deposits in the brain, which may be part of what causes Alzheimer's. Animal studies have shown that it can also kill certain cancer cells. Some animal and small human studies show that cannabinoids can have a "substantial analgesic effect," notes CNN. It may even help lessen dependency on opioids. he medical community has even looked at its impact on glaucoma patients, finding that it can help lower eye pressure and blood pressure. Researchers have even found that some cannabis chemicals may help prevent muscle spasms, pain, tremors, and stiffness in cases of multiple sclerosis. Right now, there is a clear need for medical marijuana. Since 2014, more than $1 billion has been raised by marijuana businesses. he values of these businesses have gone on an upward trajectory consistently thanks to high investments and product demand. For example, prominent marijuana producers like Aphria saw their stock skyrocket from around $5.00 this time last year to as high as $24.75 in early 2018, close to a 400% gain. Companies like Scythian Biosciences Corp. are on the right path. Potential Comparables: GW Pharmaceuticals (NASDAQ: GWPH) GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise. Its lead product candidate is Epidiolex, developed for certain rare and severe early-onset, drug-resistant epilepsy syndromes. OrganiGram Holdings Inc. (SX-V: OGI) (OCQB: OGRMF) Organigram Inc. is a licensed producer of medical marijuana in Canada. he company is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada. Its portfolio includes dry cannabis and cannabis oil, along with accessories like vaporizers. Corbus Pharmaceuticals (NASDAQ:CRBP) CRBP focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases. he company's lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug that is in Phase III clinical trials for the treatment of systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. Aphria Inc. (OCQB: APHQF) (SX:APH) Aphria is one of Canada's lowest-cost medical cannabis producers. he company sells its products through both retail and wholesale channels. It's also engaged in the research and development and commercial production of cannabis oil. DISCLAIMER: (MS) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NO affiliated with MS or any company mentioned herein. he commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NO registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NO sell, offer to sell or offer to buy any security. he Article and content related to the profiled company represent the personal and subjective views of the Author (MS), and are subject to change at any time without notice. he information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MS) has not independently verified or otherwise investigated all such information. None of the Author, MS, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. his Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated forty five hundred dollars by MS, a non-affiliated third party to distribute this release on behalf of Scythian Biosciences Corporation FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN HIS RELEASE. his release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. he forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements. submitted by /u/Lastprince416 [link] [comments]